Astria Therapeutics Inc
ATXS
Detailliertes Diagramm anzeigen
12.510USD
+0.080+0.64%
Handelsschluss 11/07, 16:00（ET）Kurse um 15 Minuten verzögert
705.99MMarktkapitalisierung
VerlustKGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
+0.64%
5 Tage
-0.95%
1 Monat
+48.05%
6 Monate
+195.74%
Seit Jahresbeginn
+39.93%
1 Jahr
+5.84%
Detailliertes Diagramm anzeigen
TradingKey Aktienbewertung von Astria Therapeutics Inc
Währung: USD Aktualisiert: 2025-11-07Wichtige Einblicke
Die Fundamentaldaten des Unternehmens sind relativ sehr gesund. Seine Bewertung wird als angemessen bewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Halten bewertet. Das Unternehmen zeigt eine starke Leistung am Aktienmarkt, mit soliden Fundamentaldaten und technischen Kennzahlen, die den Aufwärtstrend unterstützen. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Astria Therapeutics Inc Bewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
8
Analysten
Halten
Aktuelles Rating
25.833
Kursziel
+106.50%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Astria Therapeutics Inc Highlights
HöhepunkteRisiko
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.
high_profit_growth
high_profit_growth_desc%!(EXTRA string=0.00)
valuation_underestimated
valuation_underestimated_desc%!(EXTRA string=PE, string=-6.20)
institutional_decreasing_position
institutional_decreasing_position_desc%!(EXTRA string=57.81M, string=16.85%)
institutional_hold%!(EXTRA string=PRFDX)
institutional_hold_desc%!(EXTRA string=PRFDX, string=4.19K)
Astria Therapeutics Inc Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
Astria Therapeutics Inc Informationen
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.
BörsenkürzelATXS
UnternehmenAstria Therapeutics Inc
CEODr. Jill C. Milne, Ph.D.
Websitehttps://astriatx.com/
Verwandte Finanzinstrumente
-1.43%
-0.22%
+0.06%
+0.97%
-0.17%
+0.59%
+1.46%
-1.83%
-3.70%
+0.06%
+0.34%
-0.77%
-1.63%
+0.16%
-1.00%
+0.58%
0.00%
+1.65%
+0.50%
+0.57%Beliebte Symbole
